Cargando…
Phase II study of lonidamine in metastatic breast cancer.
Thirty patients with previously treated metastatic breast cancer were entered in a phase II study with oral lonidamine. Twenty-eight patients are evaluable for toxicity and 25 for response. A partial remission was obtained in four patients (16%) and disease stability in 11 (44%): 10 patients progres...
Autores principales: | Pronzato, P., Amoroso, D., Bertelli, G., Conte, P. F., Cusimano, M. P., Ciottoli, G. B., Gulisano, M., Lionetto, R., Rosso, R. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1989
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2247009/ https://www.ncbi.nlm.nih.gov/pubmed/2930690 |
Ejemplares similares
-
Phase II study of lonidamine in non-small cell lung cancer: final report.
por: Kokron, O., et al.
Publicado: (1990) -
A phase II clinical and pharmacokinetic study of Lonidamine in patients with advanced breast cancer.
por: Mansi, J. L., et al.
Publicado: (1991) -
Inhibition of Mitochondrial Complex II by the Anticancer Agent Lonidamine
por: Guo, Lili, et al.
Publicado: (2016) -
New Organometallic Ru(II) Compounds with Lonidamine Motif as Antitumor Agents
por: Shutkov, Ilya A., et al.
Publicado: (2023) -
Ru(III) Complexes with Lonidamine-Modified Ligands
por: Shutkov, Ilya A., et al.
Publicado: (2021)